A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naive Subjects With Chronic HCV GT1, GT4, GT5, and GT6 Infection Who Are on Opiate Substitution Therapy

Trial Profile

A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naive Subjects With Chronic HCV GT1, GT4, GT5, and GT6 Infection Who Are on Opiate Substitution Therapy

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Elbasvir/grazoprevir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms C-EDGE CO-STAR
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 09 May 2017 Results (n=185) of Co-STAR Three-Year Follow-up Study, presented at the Digestive Disease Week 2017
    • 12 Nov 2016 Interim results from the three year follow-up (3YFU) trial published in the Merck & Co Media Release.
    • 12 Nov 2016 Interim Results from this trial presented at The Liver Meeting 2016, as reported by a Merck & Co media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top